UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: FLXN |
| Industry | Pharmaceuticals |
| Headquarters | Burlington, MA |
| Website | Flexion Therapeutics |
Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.
It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.
In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta". In March 2017 FiercePharma reported that Flexion was in discussions with Sanofi about a possible acquisition, valued at the time at around $1 billion.
Flexion had been developing FX007, a selective small-molecule TrkA inhibitor that it had licensed from AstraZeneca, for osteoarthritis. As of March 2017 Flexion had terminated development. Flexion had also terminated development of FX005, a P38 mitogen-activated protein kinase inhibitor, by that time.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2021 | 2022-03-08 | Future report Set alerts | |
| Q3 2021 | 2021-11-12 | -0.60 | -0.60 |
| Q2 2021 | 2021-08-04 | -0.44 | -0.44 |
| Q1 2021 | 2021-05-12 | -0.57 | -0.57 |
| Q4 2020 | 2021-03-10 | -0.37 | -0.37 |
| Q3 2020 | 2020-11-04 | -0.50 | 0.00 |
| Q2 2020 | 2020-08-05 | -0.76 | -0.76 |
| Q1 2020 | 2020-05-07 | -0.95 | -0.95 |
| Q4 2019 | 2020-03-12 | -0.88 | -0.88 |
| Q3 2019 | 2019-11-07 | -1.00 | -1.00 |
| 2016-07-01 | Reiterated Rating | Janney Montgomery Scott | Buy | $30.00 |
| 2016-06-30 | Reiterated Rating | RBC Capital | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-06-30 | Reiterated Rating | Royal Bank Of Canada | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo & Co. | Buy | |
| 2016-06-28 | Initiated Coverage | BMO Capital Markets | Outperform | $35.00 |
| 2016-05-27 | Reiterated Rating | Janney Montgomery Scott | Buy | $30.00 |
| 2016-05-27 | Reiterated Rating | Needham & Company LLC | Buy | $28.00 to $34.00 |
| 2016-05-26 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-05-14 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-05-03 | Initiated Coverage | Wells Fargo | Outperform | |
| 2016-04-29 | Reiterated Rating | Cantor Fitzgerald | Buy | $44.00 |
| 2016-04-05 | Reiterated Rating | Cantor Fitzgerald | Buy | $44.00 |
| 2016-04-04 | Reiterated Rating | Needham & Company LLC | Buy | $28.00 |
| 2016-03-11 | Reiterated Rating | Cantor Fitzgerald | Buy | $44.00 |
| 2016-02-17 | Reiterated Rating | Janney Montgomery Scott | Buy | $27.00 to $33.00 |
| 2016-02-17 | Reiterated Rating | RBC Capital | Outperform | $44.00 |
| 2016-01-13 | Reiterated Rating | Cantor Fitzgerald | Buy | $44.00 |
| 2015-12-13 | Reiterated Rating | RBC Capital | Outperform | $44.00 |
| 2015-12-10 | Initiated Coverage | Janney Montgomery Scott | Buy | $27.00 |
| 2015-12-02 | Reiterated Rating | Cantor Fitzgerald | Buy | $44.00 |
| 2015-11-04 | Initiated Coverage | Cantor Fitzgerald | Buy | $44.00 |
| 2015-09-09 | Reiterated Rating | RBC Capital | Buy | |
| 2015-09-09 | Lower Price Target | Needham & Company LLC | Buy | $31.00 to $28.00 |
| 2015-09-02 | Reiterated Rating | Northland Securities | Buy | $40.00 |
| 2015-08-07 | Boost Price Target | Janney Montgomery Scott | Buy | $34.50 to $39.50 |
| 2015-07-31 | Boost Price Target | RBC Capital | Outperform | $41.00 to $44.00 |
| 2015-05-23 | Reiterated Rating | BMO Capital Markets | Outperform | $36.00 to $38.00 |
| 2015-05-14 | Initiated Coverage | Northland Securities | Outperform | $40.00 |
| 2015-03-30 | Initiated Coverage | MLV & Co. | Buy | $38.00 |
| 2015-03-24 | Boost Price Target | Janney Montgomery Scott | Buy | $30.00 to $34.50 |
| 2015-02-16 | Initiated Coverage | RBC Capital | Outperform | $37.00 |
| 2014-11-26 | Reiterated Rating | Summer Street | Buy | |
| 2014-09-10 | Boost Price Target | Needham & Company LLC | $26.00 to $31.00 | |
| 2014-09-10 | Boost Price Target | BMO Capital Markets | $33.00 to $36.00 | |
| 2014-08-14 | Initiated | Summer Street Research | Buy | $25 |
| 2014-08-14 | Initiated Coverage | Summer Street | Buy | $25.00 |
| 2014-03-19 | Initiated Coverage | Janney Montgomery Scott | Buy | $25.00 |
| 2014-03-10 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2014-03-10 | Initiated Coverage | BMO Capital Markets | Outperform | $33.00 |
| 2014-03-10 | Initiated Coverage | Needham & Company LLC | Buy | $26.00 |
| 2014-03-10 | Initiated Coverage | Wells Fargo | Outperform |
| 2016-07-01 | Reiterated Rating | Janney Montgomery Scott | Buy | $30.00 |
| 2016-06-30 | Reiterated Rating | RBC Capital | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-06-30 | Reiterated Rating | Royal Bank Of Canada | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In FLXN 19 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 1.23M |
| TPG Group Holdings (SBS) Advisors, Inc. | 0.94M |
| BlackRock Institutional Trust Company, N.A. | 0.68M |
| SELZ CAPITAL LLC | 0.34M |
| SNOW CAPITAL MANAGEMENT LP | 0.31M |
| MADISON INVESTMENT HOLDINGS INC | 0.17M |
| BlackRock Investment Management, LLC | 99002 |
| TEACHERS ADVISORS INC | 93186 |
| WALL STREET ASSOCIATES | 84700 |
| TIAA CREF INVESTMENT MANAGEMENT LLC | 84284 |
| Marshall Wace North America, L.P. | 60215 |
| BB&T SECURITIES, LLC | 25700 |
| KCG Holdings, Inc. | 17331 |
| BLACKROCK ADVISORS LLC | 13762 |
| RUSSELL FRANK CO/ | 6400 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Bolzon Bradley J PhD | 20.52% (3206807) | FLXN / |
| Novo A/S SEE REMARKS | 13.65% (2133131) | AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH / |
| Tordjman Rafael | 13.48% (2105491) | FLXN / |
| Sofinnova Partners SAS | 13.41% (2095491) | FLXN / |
| PFIZER INC | 10.80% (1687250) | AQXP / CLDN / FLXN / |
| Schwab Andrew J. | 9.68% (1512076) | FLXN / |
| 5AM Ventures II LP | 9.68% (1512076) | FLXN / |
| Bodick Neil Chief Medical Officer | 0.48% (74605) | FLXN / |
| Clayman Michael D. President and CEO | 0.41% (64728) | AKBA / FLXN / |
| LUBASH BARBARA N | 0.13% (20739) | FLXN / |
| Versant Ventures III, LLC | 0.13% (20739) | FLXN / VCYT / |
| KELLEY SCOTT Chief Medical Officer | 0.10% (14892) | FLXN / |
| Wentworth Kerry Chief Regulatory Officer | 0.08% (12307) | AGEN / FLXN / |
| Deniz Yamo Chief Medical Officer | 0.06% (9000) | FLXN / |
| Levine Mark S. SVP & General Counsel | 0.05% (8333) | FLXN / NERV / |
| DRISCOLL FREDERICK W Chief Financial Officer | 0.05% (7777) | FLXN / MEIP / NVAX / OXGN / |
| COLELLA SAMUEL D | 0.03% (5000) | ALXA / FLDM / FLXN / GHDX / VCYT / |
| Versant Venture Capital III, L.P. | 0.01% (2250) | FLXN / IMDZ / |
| MERRIFIELD C ANN | 0.01% (2000) | CBRX / FLXN / |
| Stejbach Mark | 0.01% (1580) | ALKS / FLXN / TNGN / |
UM